This study was designed to evaluate the effects of low-frequency electroacupuncture (EA) on glucose and lipid disturbances in a rat model of polycystic ovary syndrome (PCOS) characterized by insulin resistance (IR) and hepatic steatosis.
Methods:
The PCOS rat model was induced by continuous administration of letrozole (LET) combined with a high-fat diet (HFD). Female Sprague–Dawley rats were divided into the following four groups: control, control + EA, LET + HFD and LET + HFD + EA. EA was administered five or six times a week with a maximum of 20 treatment sessions. Body weight, estrous cyclicity, hormonal status, glucose and insulin tolerance, lipid profiles, liver inflammation factors, liver morphology and changes in the phosphatidylinositol 3-kinase (PI3-K)/Akt (protein kinase B) pathway were evaluated.
Results:
The rat model presented anovulatory cycles, increased body weight, elevated testosterone, abnormal glucose and lipid metabolism, IR, liver inflammation, hepatic steatosis and dysregulation of the insulin-mediated PI3-K/Akt signaling axis. EA reduced fasting blood glucose, fasting insulin, area under the curve for glucose, homeostasis model assessment of IR indices, triglycerides and free fatty acids, and alleviated hepatic steatosis. Furthermore, low-frequency EA downregulated mRNA expression of tumor necrosis factor (TNF)-α and interleukin (IL)-6, upregulated mRNA expression of peroxisome proliferator-activated receptor (PPAR)-α, increased protein expression of phosphorylated (p)-Akt (Ser473), p-glycogen synthase kinase (GSK) 3β (Ser9) and glucose transporter 4 (GLUT4), increased the ratio of p-GSK3β to GSK3β and downregulated protein expression of GSK3β.
Conclusion:
An obese PCOS rat model with IR and hepatic steatosis was successfully established by the combination of LET and HFD. EA improved dysfunctional glucose and lipid metabolism in this PCOS-IR rat model, and the molecular mechanism appeared to involve regulation of the expression of key molecules of the PI3-K/Akt insulin signaling pathway in the liver.
PaschouSAPolyzosSAAnagnostisP, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine2020; 67(1): 1–8.
3.
MessinisIEMessiniCIAnifandisG, et al. Polycystic ovaries and obesity. Best Pract Res Clin Obstet Gynaecol2015; 29(4): 479–488.
4.
FreemanAMPenningsN.Insulin resistance. Treasure Island, FL: Statpearls, 2022.
5.
SteptoNKCassarSJohamAE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod2013; 28(3): 777–784.
6.
MoranLJMissoMLWildRA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update2010; 16(4): 347–363.
7.
WangCDingCHuaZ, et al. Cangfudaotan decoction alleviates insulin resistance and improves follicular development in rats with polycystic ovary syndrome via IGF-1-PI3K/Akt-Bax/Bcl-2 pathway. Mediators Inflamm2020; 2020: 8865647.
8.
DuHZhaoAQiW, et al. Supplementation of inulin with various degree of polymerization ameliorates liver injury and gut microbiota dysbiosis in high fat-fed obese mice. J Agr Food Chem2020; 68(3): 779–787.
9.
MacutDBjekic-MacutJLivadasS, et al. Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome. Curr Pharm Des2018; 24(38): 4593–4597.
10.
MacutDBožić-AntićIBjekić-MacutJ, et al. Management of endocrine disease: polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol2017; 177(3): R145–R158.
11.
LiMChiXWangY, et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther2022; 7(1): 216.
12.
JacksonWPCoetzeeEJ.Side-effects of metformin. South Af Med J1979; 56(26): 1113.
13.
NoureddinMZhangALoombaR.Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs2016; 21(3): 343–357.
14.
PengYYangXLuoX, et al. Novel mechanisms underlying anti-polycystic ovary like syndrome effects of electroacupuncture in rats: suppressing SREBP1 to mitigate insulin resistance, mitochondrial dysfunction and oxidative stress. Biol Res2020; 53(1): 1–50.
15.
XuGZhangALiuJ, et al. Effects of electroacupuncture on ovarian expression of the androgen receptor and connexin 43 in rats with letrozole-induced polycystic ovaries. Evid Based Complement Alternat Med2020; 2020: 3608062.
16.
BenrickAKokosarMHuM, et al. Autonomic nervous system activation mediates the increase in whole-body glucose uptake in response to electroacupuncture. FASEB J2017; 31(8): 3288–3297.
17.
LiBFangL.Research progress on the mechanism of acupuncture treatment for nonalcoholic fatty liver disease. Gastroenterol Res Pract2022; 2022: 5259088.
18.
SebayangRGAdityaCAbdurrohimK, et al. Effects of laser acupuncture and dietary intervention on key obesity parameters. Med Acupunct2020; 32(2): 108–115.
19.
XuTYuZLiuY, et al. Hypoglycemic effect of electroacupuncture at ST25 through neural regulation of the pancreatic intrinsic nervous system. Mol Neurobiol2022; 59(1): 703–716.
20.
HanXChenXWangX, et al. Electroacupuncture at ST36 improve the gastric motility by affecting neurotransmitters in the enteric nervous system in type 2 diabetic rats. Evid Based Complement Alternat Med2021; 2021: 6666323.
21.
WenQHuMLaiM, et al. Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial. Hum Reprod2022; 37(3): 542–552.
22.
BegumNManipriyaKVeereshB.Role of high-fat diet on letrozole-induced polycystic ovarian syndrome in rats. Eur J Pharmacol2022; 917: 174746.
23.
PatelRShahG.High-fat diet exposure from pre-pubertal age induces polycystic ovary syndrome (PCOS) in rats. Reproduction2018; 155(2): 141–151.
24.
MarcondesFKBianchiFJTannoAP.Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol2002; 62(4A): 609–614.
25.
DeugarteCBartolucciAAzzizR.Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril2005; 83(5): 1454–1460.
26.
KleinerDEBruntEMVan NattaM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology2005; 41(6): 1313–1321.
27.
DeutschMJSchrieverSCRoscherAA, et al. Digital image analysis approach for lipid droplet size quantitation of oil red O-stained cultured cells. Anal Biochem2014; 445: 87–89.
28.
ShankarKMetzgerNPSinghO, et al. LEAP2 deletion in mice enhances ghrelin’s actions as an orexigen and growth hormone secretagogue. Mol Metab2021; 53: 101327.
29.
NoroozzadehMBehboudi-GandevaniSZadeh-VakiliA, et al. Hormone-induced rat model of polycystic ovary syndrome: a systematic review. Life Sciences (1973)2017; 191: 259–272.
30.
ShiDVineDF.Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertil Steril2012; 98(1): 185–193.
31.
LeeBHIndranIRTanHM, et al. A dietary medium-chain fatty acid, decanoic acid, inhibits recruitment of Nur77 to the HSD3B2 promoter in vitro and reverses endocrine and metabolic abnormalities in a rat model of polycystic ovary syndrome. Endocrinology2016; 157(1): 382–394.
32.
MaliqueoMSunMJohanssonJ, et al. Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology2013; 154(1): 434–445.
33.
PatelRShahG.Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome. Mol Reprod Dev2018; 85(10): 778–789.
34.
OnoH.Molecular mechanisms of hypothalamic insulin resistance. Int J Mol Sci2019; 20(6): 1317.
35.
LiJWuWStener-VictorinE, et al. A prospective pilot study of the effect of acupuncture on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance. Acupunct Med2020; 38(5): 310–318.
36.
XuJChenLTangL, et al. Electroacupuncture inhibits weight gain in diet-induced obese rats by activating hypothalamic LKB1-AMPK signaling. Bmc Complem Altern M2015; 15: 147.
37.
GongLGuoSZouZ.Resveratrol ameliorates metabolic disorders and insulin resistance in high-fat diet-fed mice. Life Sci2020; 242: 117212.
38.
SilvaGFerraresiCde AlmeidaRT, et al. Insulin resistance is improved in high-fat fed mice by photobiomodulation therapy at 630 nm. J Biophotonics2020; 13(3): e201960140.
39.
SongHLaiJTangQ, et al. Mulberry ethanol extract attenuates hepatic steatosis and insulin resistance in high-fat diet-fed mice. Nutr Res2016; 36(7): 710–718.
40.
MaBLiPAnH, et al. Electroacupuncture attenuates liver inflammation in nonalcoholic fatty liver disease rats. Inflammation2020; 43(6): 2372–2378.
41.
ShengDZhaoSGaoL, et al. BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling. Cell Biosci2019; 9: 77.
42.
MunJKimSYoonHG, et al. Water extract of Curcuma longa L. Ameliorates non-alcoholic fatty liver disease. Nutrients2019; 11(10): 2536.
43.
WangZYangLDongH, et al. Effect of electroacupuncture on the kisspeptin system in a pubertal rat model of polycystic ovary syndrome. Acupunct Med2021; 39(5): 491–500.
44.
GuoS.Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol2014; 220(2): T1–T23.
45.
TitchenellPMQuinnWJLuM, et al. Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab2016; 23(6): 1154–1166.
46.
LiTMoHChenW, et al. Role of the PI3K-Akt signaling pathway in the pathogenesis of polycystic ovary syndrome. Reprod Sci2017; 24(5): 646–655.
47.
ZhangYMengFSunX, et al. Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. Oncotarget2018; 9(26): 18180–18197.
48.
ZhengXZhaoMGJiangCH, et al. Triterpenic acids-enriched fraction from cyclocarya paliurus attenuates insulin resistance and hepatic steatosis via PI3K/Akt/GSK3beta pathway. Phytomedicine2020; 66: 153130.
49.
HuangSTangNZhaoH, et al. Effect of electrical stimulation combined with diet therapy on insulin resistance via mTOR signaling. Mol Med Rep2019; 20(6): 5152–5162.
50.
ChengCLiuXHHeJ, et al. Apolipoprotein A4 restricts diet-induced hepatic steatosis via SREBF1-mediated lipogenesis and enhances IRS-PI3K-Akt signaling. Mol Nutr Food Res2022; 66(18): e2101034.
